ECSP14000074A - Mètodos para preparar anàlogos nucleotìdicos antivirales - Google Patents

Mètodos para preparar anàlogos nucleotìdicos antivirales

Info

Publication number
ECSP14000074A
ECSP14000074A ECIEPI201474A ECSP14000074A ECSP14000074A EC SP14000074 A ECSP14000074 A EC SP14000074A EC IEPI201474 A ECIEPI201474 A EC IEPI201474A EC SP14000074 A ECSP14000074 A EC SP14000074A EC SP14000074 A ECSP14000074 A EC SP14000074A
Authority
EC
Ecuador
Prior art keywords
methods
nucleothical
analogues
preparing antiviral
see graph
Prior art date
Application number
ECIEPI201474A
Other languages
English (en)
Inventor
Corp Mandom
Pública De Turismo Ciudad Mitad Del Mundo Empresa
Capital Group Companies Inc The
Holger Karsunky
Nicole White
Original Assignee
Under Armour Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Under Armour Inc filed Critical Under Armour Inc
Publication of ECSP14000074A publication Critical patent/ECSP14000074A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Métodos para aislar 9–{(R)–2–[((S)–{[(S)–1–(isopropoxicarbonil)etil]amino}-fenoxifosfinil)metoxi]propil}adenina (compuesto 16): (ver grafico) ;un método para preparar, con pureza diastereomérica elevada, los compuestos intermedios 13 y 15: (ver gráfico); y un método para preparar el compuesto intermedio 12: (ver gráfico); 9–{(R)–2–[((S)–{[(S)–1–(isopropoxicarbonil)etil]amino}fenoxifosfinil)metoxi]-propil}adenina tiene propiedades antivirales.
ECIEPI201474A 2011-10-07 2014-05-05 Mètodos para preparar anàlogos nucleotìdicos antivirales ECSP14000074A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161544950P 2011-10-07 2011-10-07

Publications (1)

Publication Number Publication Date
ECSP14000074A true ECSP14000074A (es) 2016-01-29

Family

ID=47297386

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201474A ECSP14000074A (es) 2011-10-07 2014-05-05 Mètodos para preparar anàlogos nucleotìdicos antivirales

Country Status (25)

Country Link
US (4) US8664386B2 (es)
EP (2) EP3333173B1 (es)
JP (2) JP6190372B2 (es)
KR (3) KR20200090975A (es)
CN (4) CN113264959A (es)
AR (1) AR088109A1 (es)
AU (1) AU2012319172B2 (es)
BR (1) BR112014011340A2 (es)
CA (2) CA3042169C (es)
CL (1) CL2014000827A1 (es)
CO (1) CO6940431A2 (es)
CR (1) CR20140204A (es)
EA (1) EA027086B1 (es)
EC (1) ECSP14000074A (es)
ES (2) ES2661705T3 (es)
HK (3) HK1255222B (es)
IL (1) IL231879B (es)
MX (1) MX353064B (es)
PE (1) PE20141160A1 (es)
PL (1) PL3333173T3 (es)
PT (2) PT3333173T (es)
SI (1) SI3333173T1 (es)
TW (4) TWI557133B (es)
UY (1) UY34361A (es)
WO (1) WO2013052094A2 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55353B2 (sr) 2011-08-16 2023-11-30 Gilead Sciences Inc Tenofovir alafenamid hemifumarat
CN113264959A (zh) * 2011-10-07 2021-08-17 吉利德科学公司 制备抗病毒核苷酸类似物的方法
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US9676803B2 (en) 2013-06-07 2017-06-13 Cipla Limited Efficient process for separation of diastereomers of 9-[(R)-2-[[(R,S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine
CN104628773B (zh) * 2013-11-06 2018-10-23 杭州和泽医药科技有限公司 (r)-9-[2-(磷酰苯酚基甲氧基)丙基]腺嘌呤的制备方法
WO2015079455A2 (en) * 2013-11-27 2015-06-04 Laurus Labs Private Limited A recycling process for preparing tenofovir alafenamide diastereomers
EP3077404B1 (en) * 2014-01-14 2020-10-07 Mylan Laboratories Ltd. Purification of tenofovir alafenamide and its intermediates
TWI660965B (zh) 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
CN105531281B (zh) * 2014-04-21 2017-12-15 四川海思科制药有限公司 一种核苷类似物及其中间体的制备方法
WO2015197006A1 (zh) * 2014-06-25 2015-12-30 四川海思科制药有限公司 一种取代的氨基酸硫酯类化合物、其组合物及应用
CN105399771B (zh) * 2014-07-21 2020-11-24 江苏豪森药业集团有限公司 替诺福韦前药晶型及其制备方法和用途
CN105646584B (zh) * 2014-11-12 2018-09-28 四川海思科制药有限公司 替诺福韦艾拉酚胺富马酸盐晶型及其制备方法和用途
CN104817593B (zh) * 2015-04-27 2016-11-16 广州同隽医药科技有限公司 半富马酸替诺福韦艾拉酚胺关键中间体的合成工艺
JP6978406B2 (ja) 2015-08-05 2021-12-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 均質オリゴマーを調製するためのキラル試薬
TWI616452B (zh) * 2015-08-26 2018-03-01 Preparation method of nucleoside analog and intermediate thereof
CN105330700A (zh) * 2015-12-17 2016-02-17 中国药科大学 富马酸替诺福韦艾拉酚胺杂质的制备方法
WO2017118928A1 (en) 2016-01-06 2017-07-13 Lupin Limited Process for the separation of diastereomers of tenofovir alafenamide
CZ2016156A3 (cs) * 2016-03-17 2017-09-27 Zentiva, K.S. Způsob přípravy diastereomerně čistého Tenofoviru Alafenamidu nebo jeho solí
CN107286190A (zh) * 2016-04-13 2017-10-24 刘沛 核苷之烃氧基苄基氨基磷酸/膦酸酯衍生物的制备及其医药用途
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN106565785B (zh) * 2016-11-09 2019-11-12 周雨恬 一种具有抗hbv/hiv活性的核苷氨基磷酸酯类化合物及其盐和用途
CN106946935B (zh) * 2017-04-28 2020-01-07 福建广生堂药业股份有限公司 一种非对映异构体核苷衍生物的制备方法
EP3692041A1 (en) * 2017-10-04 2020-08-12 Celgene Corporation Processes for the preparation of cis-4 [2-{(3s.4r)-3-fluorooxan-4-yl]amino)-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
CN109942633B (zh) * 2017-12-20 2021-08-31 上海新礼泰药业有限公司 替诺福韦艾拉酚胺中间体的制备方法
CN109942632B (zh) * 2017-12-20 2021-08-31 上海博志研新药物研究有限公司 替诺福韦艾拉酚胺中间体的制备方法
CN110092803A (zh) * 2018-01-31 2019-08-06 北京睿创康泰医药研究院有限公司 替诺福韦艾拉酚胺富马酸盐工艺杂质的制备及其应用
CN108409788B (zh) * 2018-03-12 2020-05-08 科兴生物制药股份有限公司 一种富马酸替诺福韦艾拉酚胺的制备方法
CN110305163A (zh) * 2018-03-27 2019-10-08 北京济美堂医药研究有限公司 替诺福韦艾拉酚胺半富马酸盐的制备方法
CN108467410B (zh) * 2018-04-09 2021-04-09 重庆三圣实业股份有限公司 一种taf中间体的制备方法及产品和应用
CN108484672A (zh) * 2018-05-23 2018-09-04 中国药科大学制药有限公司 磷丙替诺福韦的手性拆分方法
CN108822149B (zh) * 2018-06-01 2020-08-11 成都苑东生物制药股份有限公司 一种富马酸替诺福韦艾拉酚胺关键中间体的制备方法
CN110283208B (zh) * 2018-06-22 2022-07-08 南京济群医药科技股份有限公司 一种替诺福韦艾拉酚胺的手性拆分方法
CN109081853A (zh) * 2018-09-03 2018-12-25 南京正大天晴制药有限公司 一种磷丙替诺福韦有关物质的制备方法
CN111484527A (zh) * 2019-01-25 2020-08-04 上海清松制药有限公司 一种替诺福韦艾拉酚胺中间体的制备方法
CN111943981A (zh) * 2019-05-14 2020-11-17 博瑞生物医药泰兴市有限公司 一种磷丙替诺福韦的制备方法
CN114409706B (zh) * 2019-07-01 2023-11-28 上海医药工业研究院 一种苯基氢膦酸酯及其中间体的制备方法
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
CN112390824B (zh) * 2019-08-19 2022-07-05 鲁南制药集团股份有限公司 一种替诺福韦艾拉酚胺中间体的制备方法
CN110981911A (zh) * 2019-10-08 2020-04-10 浙江车头制药股份有限公司 一种替诺福韦艾拉酚胺的制备方法
CN111171076A (zh) * 2019-12-26 2020-05-19 合肥启旸生物科技有限公司 一种替诺福韦二聚体的制备方法
EP4121437A1 (en) 2020-03-20 2023-01-25 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
KR20210125298A (ko) 2020-04-08 2021-10-18 주식회사 파마코스텍 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법
CN116437958A (zh) 2020-11-11 2023-07-14 吉利德科学公司 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法
KR20220141457A (ko) 2021-04-13 2022-10-20 경동제약 주식회사 신규 결정형의 테노포비어 알라펜아미드 말레산염 및 이를 포함하는 약제학적 조성물
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TW202402280A (zh) 2022-07-01 2024-01-16 美商基利科學股份有限公司 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
US20240083984A1 (en) 2022-08-26 2024-03-14 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1301519T4 (da) * 2000-07-21 2021-12-20 Gilead Sciences Inc Prodrugs af phosphonatnukleotidanaloger og fremgangsmåder til udvælgelse og fremstilling heraf
US20050239054A1 (en) * 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
SI2258376T1 (sl) 2004-07-27 2019-04-30 Gilead Sciences, Inc. Analogi fosfonata spojin inhibitorjev HIV
DK1999133T3 (da) * 2006-03-29 2013-11-25 Gilead Sciences Inc Fremgangsmåde til fremstilling af HIV-proteaseinhibitorer
JP5356228B2 (ja) * 2006-07-07 2013-12-04 ギリアード サイエンシーズ， インコーポレイテッド ｔｏｌｌ様レセプター７の調節因子
EP2049547A2 (en) * 2006-07-21 2009-04-22 Gilead Sciences, Inc. Aza-peptide protease inhibitors
US8106064B2 (en) * 2006-07-24 2012-01-31 Korea Research Institute Of Chemical Technology Pyrimidine-2,4-dione HIV reverse transcriptase inhibitors
WO2009005693A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Novel hiv reverse transcriptase inhibitors
RS55353B2 (sr) 2011-08-16 2023-11-30 Gilead Sciences Inc Tenofovir alafenamid hemifumarat
CN113264959A (zh) 2011-10-07 2021-08-17 吉利德科学公司 制备抗病毒核苷酸类似物的方法

Also Published As

Publication number Publication date
CN117343101A (zh) 2024-01-05
NZ624513A (en) 2016-06-24
MX2014003952A (es) 2014-08-01
TWI613211B (zh) 2018-02-01
CA3042169A1 (en) 2013-04-11
EA201490753A1 (ru) 2014-09-30
CN107266498A (zh) 2017-10-20
MX353064B (es) 2017-12-19
KR102033802B1 (ko) 2019-10-17
EA027086B1 (ru) 2017-06-30
ES2661705T3 (es) 2018-04-03
US20130090473A1 (en) 2013-04-11
CO6940431A2 (es) 2014-05-09
US8664386B2 (en) 2014-03-04
TW201331218A (zh) 2013-08-01
TWI557133B (zh) 2016-11-11
CN113264959A (zh) 2021-08-17
EP3333173A1 (en) 2018-06-13
AU2012319172A1 (en) 2013-05-16
US20140128602A1 (en) 2014-05-08
EP2764002B1 (en) 2018-02-28
TW201716418A (zh) 2017-05-16
US9676804B2 (en) 2017-06-13
PL3333173T3 (pl) 2019-12-31
TW201811808A (zh) 2018-04-01
CN103842366B (zh) 2017-06-16
TWI709567B (zh) 2020-11-11
KR102139440B1 (ko) 2020-07-29
US9029534B2 (en) 2015-05-12
BR112014011340A2 (pt) 2017-06-13
JP6190372B2 (ja) 2017-08-30
HK1200834A1 (en) 2015-08-14
CA3042169C (en) 2021-09-07
KR20200090975A (ko) 2020-07-29
CN103842366A (zh) 2014-06-04
EP3333173B1 (en) 2019-06-26
TW202003531A (zh) 2020-01-16
UY34361A (es) 2013-05-31
US20150291638A1 (en) 2015-10-15
HK1255222B (zh) 2020-07-17
AU2012319172B2 (en) 2014-06-12
ES2746859T3 (es) 2020-03-09
JP2017160228A (ja) 2017-09-14
IL231879B (en) 2019-11-28
AR088109A1 (es) 2014-05-07
KR20140090170A (ko) 2014-07-16
CA2850466C (en) 2020-07-28
TWI689513B (zh) 2020-04-01
CA2850466A1 (en) 2013-04-11
EP2764002A2 (en) 2014-08-13
PE20141160A1 (es) 2014-09-22
CR20140204A (es) 2014-06-03
CN107266498B (zh) 2023-10-03
PT2764002T (pt) 2018-05-16
WO2013052094A2 (en) 2013-04-11
SI3333173T1 (sl) 2019-08-30
US9346841B2 (en) 2016-05-24
HK1245798A1 (zh) 2018-08-31
JP2014530809A (ja) 2014-11-20
WO2013052094A3 (en) 2013-06-20
KR20190086576A (ko) 2019-07-22
PT3333173T (pt) 2019-09-10
US20160311840A1 (en) 2016-10-27
CL2014000827A1 (es) 2014-09-05

Similar Documents

Publication Publication Date Title
ECSP14000074A (es) Mètodos para preparar anàlogos nucleotìdicos antivirales
PH12015501934A1 (en) New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors
BR112014003220A2 (pt) composto de fórmula (i), processo para preparar um composto de fórmula i e v, uso do composto de fórmula i, método para controlar uma praga invertebrada, forma cristalina, uso das formas cristalinas e método para controlar uma praga invertebrada
CY20152200001T2 (el) Μεθοδοι για την αντιμετωπιση του hcv οι οποιες περιλαμβανουν τουλαχιστον δυο αμεσης δρασης αντιϊκους παραγοντες, ριμπαβιρινη, αλλα οχι ιντερφερονη
PE20171444A1 (es) Compuestos antivirales
MD20180040A2 (ro) Inhibitori ai virusului hepatic C
CO6680607A2 (es) Métodos para la preparación de profármacos de fosforamidato diastereoméricamente puros
CR20140132A (es) Derivados de pirrolopirimidina y purina
UA113643C2 (xx) N-цикліламіди як нематоциди
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
GT201300021A (es) Proceso para preparar compuestos antivirales
BR112013030830A2 (pt) processo de preparação de composto da fórmula (i) e estetrol obtido diretamente por meio do processo
IN2013MU01967A (es)
BR112013030833A2 (pt) processo para a preparação de um composto de formula (i) e processo para a preparação de estetrol
UY34245A (es) Compuestos antivirales para el tratamiento de la hepatitis c (hcv), y métodos de tratamiento.
CR20140078A (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)
ES2603227T3 (es) Proceso para la preparación de compuestos cetólidos
IN2014CN04960A (es)
BR112013013028A2 (pt) processo para a preparação de derivados de carbamato de fenila
IN2014DN00144A (es)
ECSP13012914A (es) Síntesis de derivados de 2-carboxamida-cicloamino-urea
PH12014501353B1 (en) Method for preparing cysteine or a derivative thereof using a novel o-phosphoserine sulfhydrylase
MX2013014969A (es) Metodo para preparar zeolitas tipo lta utilizando un agente director de estructura novedoso.
PH12014501327A1 (en) Processes for making magnolol analogs
MX2016014644A (es) Metodo para preparar penams.